HUGE

FSD PharmaCNSX:HUGE Stock Report

Market Cap

CA$72.4m

7D

-6.0%

1Y

-44.5%

Updated

18 Sep, 2021

Data

Company Financials
HUGE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

HUGE Overview

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company.

FSD Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for FSD Pharma
Historical stock prices
Current Share PriceCA$2.02
52 Week HighCA$1.70
52 Week LowCA$5.25
Beta1.1
1 Month Change5.76%
3 Month Change-11.40%
1 Year Change-44.51%
3 Year Change-98.87%
5 Year Changen/a
Change since IPO-91.63%

Recent News & Updates

Aug 25
Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

HUGECA PharmaceuticalsCA Market
7D-6.0%1.7%-0.6%
1Y-44.5%29.2%28.9%

Return vs Industry: HUGE underperformed the Canadian Pharmaceuticals industry which returned 29.2% over the past year.

Return vs Market: HUGE underperformed the Canadian Market which returned 29% over the past year.

Price Volatility

Is HUGE's price volatile compared to industry and market?
HUGE volatility
HUGE Beta1.1
Industry Beta1.85
Market Beta1

Stable Share Price: HUGE is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: HUGE's weekly volatility has decreased from 13% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19989Anthony Durkaczhttps://www.fsdpharma.com

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders.

FSD Pharma Fundamentals Summary

How do FSD Pharma's earnings and revenue compare to its market cap?
HUGE fundamental statistics
Market CapUS$56.78m
Earnings (TTM)-US$38.53m
Revenue (TTM)n/a

0x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HUGE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$38.53m
Earnings-US$38.53m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.64
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.5%

How did HUGE perform over the long term?

See historical performance and comparison

Valuation

Is FSD Pharma undervalued compared to its fair value and its price relative to the market?

0.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HUGE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HUGE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HUGE is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.

PE vs Market: HUGE is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HUGE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HUGE is good value based on its PB Ratio (1x) compared to the CA Pharmaceuticals industry average (2.6x).


Future Growth

How is FSD Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

44.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as FSD Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has FSD Pharma performed over the past 5 years?

-46.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HUGE is currently unprofitable.

Growing Profit Margin: HUGE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HUGE is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.

Accelerating Growth: Unable to compare HUGE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HUGE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).


Return on Equity

High ROE: HUGE has a negative Return on Equity (-66.11%), as it is currently unprofitable.


Financial Health

How is FSD Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: HUGE's short term assets ($54.1M) exceed its short term liabilities ($10.0M).

Long Term Liabilities: HUGE's short term assets ($54.1M) exceed its long term liabilities ($61.6K).


Debt to Equity History and Analysis

Debt Level: HUGE's debt to equity ratio (0.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if HUGE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HUGE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HUGE has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 24.5% each year.


Dividend

What is FSD Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HUGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HUGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HUGE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HUGE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HUGE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average management tenure


CEO

Anthony Durkacz (45 yo)

0.17

Tenure

US$529,663

Compensation

Mr. Anthony John Durkacz has been Executive Vice President and Director at First Republic Capital Corp., since January 2014. Mr. Durkacz served as the President of Capital Ideas Investor Relations from Jan...


Leadership Team

Experienced Management: HUGE's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: HUGE's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 143.4%.


Top Shareholders

Company Information

FSD Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: FSD Pharma Inc.
  • Ticker: HUGE
  • Exchange: CNSX
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$72.388m
  • Shares outstanding: 35.84m
  • Website: https://www.fsdpharma.com

Number of Employees


Location

  • FSD Pharma Inc.
  • First Canadian Place
  • Suite 3400
  • Toronto
  • Ontario
  • M5X 1A4
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 22:16
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.